A broader view of MRD

We combine broad whole-genome tumor data with sophisticated AI to transform how cancer is monitored.

Our solution utilizes a combination of AI pattern recognition and whole-genome sequencing to provide fast and accurate detection of residual disease. This approach requires less blood and offers faster results, leading to earlier detection and improved outcomes. By adopting a whole-genome approach, we can detect cancer variants occurring across the entire genome. Our first MRD test will be for muscle invasive bladder cancer. If you would like to receive updates, please contact us.

Our platform

Veracyte MRD assay and AI-driven pipeline

We use whole genome sequencing to characterize the complete set of cancer mutations in the tumor tissue sample and blood (also called landmark), and then apply artificial intelligence to detect if there are traces of cancer in subsequent blood samples during follow up.

More data. Deeper insights.

Overview

Across the entire genome, we identify the genetic pattern of a patient’s cancer across thousands of data points, using our proprietary computation and AI methods to develop an in silico patient-specific signature. Because we are doing this using whole-genome data we save time compared to methods that require the develop of a patient-specific bespoke panel, without sacrificing performance. The genomic signature developed allows accurate and robust tracking of tumor progression as it evolves during patient treatment and follow up.

FEATURED PUBLICATIONS

In JCO: “Lab validation of an ultrasensitive ctDNA pan-cancer MRD assay using whole-genome sequencing.”

JCO publication on pan cancer MRD validation
All clinical data

Serve more of the patient journey

A differentiated WGS-based platform for MRD

Icon of two people, representing “innovate collaboratively” principle

Less blood

Uses just one tube of blood (<4ml plasma)

Icon of a graph line going up, representing “rigorously raise the bar” principle

Faster results

Results in days vs weeks using AI driven, in silico signatures

Icon representing a diagram, to represent companion diagnostics.

Earlier detection

Widest view of the tumor genetic landscape using whole genome sequencing

Icon of a magnifying glass, representing “better data, better insights” principle

Better outcomes

Faster results with deeper insights to inform care decisions

Featured events

Learn more about MRD Technology by meeting with us at upcoming events.

View all events

Contact us

Opportunities for Collaboration

We are looking to collaborate with therapeutic partners and clinical researchers who are interested in utilizing the Veracyte MRD Assay in their research projects and development work. Our collaborations can take various forms, and we have the capability to operate across multiple geographies. If you have a project that might benefit from this technology, please get in touch with us using the email address below.

MRD Technology Opportunities: [email protected]

References

  1. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
  2. Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinoma
  3. Whole genome cell-free tumor DNA mutational signatures from blood for early detection of recurrence of low stage lung adenocarcinoma